New shot method for Alpha-1 lung disease shows promise in early trial
NCT ID NCT04722887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to give Alpha-1 protein therapy by injecting it under the skin instead of into a vein. Seventeen adults with Alpha-1 Antitrypsin Deficiency received either a low or high dose weekly for eight weeks. The main goal was to check safety and how the drug moves through the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Medical University of South Carolina - Children's Hospital
Charleston, South Carolina, 29425, United States
-
UCLA Medical Center
Los Angeles, California, 90025, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Miami
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a higher dose slow lung damage in Alpha-1 patients?
- 500 adults to help unravel mysteries of rare liver disease
- New drug aims to stop liver scarring in Alpha-1 patients
- New drug could slow liver damage in rare genetic disease
- New drug shows promise for slowing liver damage in rare genetic disease